Commentary: Review compromises cancer drug development

05/29/2008 | Wall Street Journal (free content), The

A decision by Sen. Charles Grassley, R-Iowa, will have a disastrous effect on the U.S. cancer drug pipeline, Dr. Mark Thornton writes in The Wall Street Journal. Grassley has asked the Government Accountability Office to investigate the FDA's fast-track approval of Avastin, a breast cancer drug, and the agency's use of "surrogate endpoints" in regulatory approvals. The senator's demand for a complete review of every FDA-approved drug undermines the agency's authority in ensuring product safety and comes at a time when the development of new products "is longer and costlier than the last," writes Thornton, a former medical officer at the FDA's Office of Oncology Products.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park